Skip to main content
Top
Published in: Archives of Gynecology and Obstetrics 3/2010

01-03-2010 | Reproductive Medicine

Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients

Authors: Levent Kebapcilar, Oktay Bilgir, Cuneyt Eftal Taner, Ayse Gul Kebapcilar, Didem L. Kozaci, Ahmet Alacacioglu, Yasar Yildiz, Arif Yuksel, Ismail Sari

Published in: Archives of Gynecology and Obstetrics | Issue 3/2010

Login to get access

Abstract

Background

The present study was designed to determine the effect of oral contraceptives (OCP) and OCP plus spironolactone (Sp) on plasma soluble CD40L levels in polycystic ovary syndrome (PCOS) patients.

Methods

Fifty-six women with PCOS were randomized into two treatment protocols: ethinylestradiol + cyproterone acetate (2 mg, EE/CA; n = 28), and EE/CA with spironolactone (Sp; n = 28). Plasma sCD40L levels were measured before and after a 3-month treatment.

Results

Before the initiation of treatment, the sCD40L levels were not significantly different between the groups [EE/CA (1.33 ng/mL) vs. EE/CA + Sp (1.23 ng/mL); P > 0.05]. In the post-treatment period, sCD40L concentrations were increased compared with pre-treatment values in the EE/CA and EE/CA + Sp groups (1.33 vs. 2.70 ng/mL, P = 0.011; and 1.23 vs. 2.41 ng/mL, P = 0.017; respectively).

Conclusion

Increased plasma concentrations of sCD40L are associated with OCP and OCP + Sp treatment regimens in PCOS patients.
Literature
2.
go back to reference Doring A, Frohlich M, Lowel H, Koenig W (2004) Third generation oral contraceptive use and cardiovascular risk factors. Atherosclerosis 172:281–286CrossRefPubMed Doring A, Frohlich M, Lowel H, Koenig W (2004) Third generation oral contraceptive use and cardiovascular risk factors. Atherosclerosis 172:281–286CrossRefPubMed
3.
go back to reference Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, Rosendaal FR (2001) Oral contraceptives and the risk of venous thrombosis. N Engl J Med 344:1527–1535CrossRefPubMed Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, Rosendaal FR (2001) Oral contraceptives and the risk of venous thrombosis. N Engl J Med 344:1527–1535CrossRefPubMed
4.
go back to reference Karakurt F, Gumus II, Bavbek N, Kargili A, Koca C, Selcoki Y, Ozbek M, Kosar A, Akcay A (2008) Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome. Gynecol Endocrinol 24:491–497CrossRefPubMed Karakurt F, Gumus II, Bavbek N, Kargili A, Koca C, Selcoki Y, Ozbek M, Kosar A, Akcay A (2008) Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome. Gynecol Endocrinol 24:491–497CrossRefPubMed
5.
go back to reference Kebapcilar L, Taner CE, Kebapcilar AG, Sari I (2009) High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet 280:187–193CrossRefPubMed Kebapcilar L, Taner CE, Kebapcilar AG, Sari I (2009) High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet 280:187–193CrossRefPubMed
6.
go back to reference Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25
7.
go back to reference Yalcin AI, Dincer M, Aslan V, Gulbas Z (2002) Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res 25:260–264CrossRefPubMed Yalcin AI, Dincer M, Aslan V, Gulbas Z (2002) Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res 25:260–264CrossRefPubMed
8.
go back to reference Sawathiparnich P, Murphey LJ, Kumar S, Vaughan DE, Brown NJ (2003) Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. J Clin Endocrinol Metab 88:3867–3873CrossRefPubMed Sawathiparnich P, Murphey LJ, Kumar S, Vaughan DE, Brown NJ (2003) Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. J Clin Endocrinol Metab 88:3867–3873CrossRefPubMed
9.
go back to reference Mach F, Schonbeck U, Libby P (1998) CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis 137 Suppl:S89–S95CrossRefPubMed Mach F, Schonbeck U, Libby P (1998) CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis 137 Suppl:S89–S95CrossRefPubMed
10.
go back to reference André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR (2002) Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106:896–899CrossRefPubMed André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR (2002) Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106:896–899CrossRefPubMed
11.
go back to reference Oktem M, Ozcimen EE, Uckuyu A, Esinler I, Pamuk B, Bayraktar N, Kulaksizoglu S, Zeyneloglu HB (2009) Polycystic ovary syndrome is associated with elevated plasma soluble CD40 ligand, a marker of coronary artery disease. Fertil Steril 91:2545–2550CrossRefPubMed Oktem M, Ozcimen EE, Uckuyu A, Esinler I, Pamuk B, Bayraktar N, Kulaksizoglu S, Zeyneloglu HB (2009) Polycystic ovary syndrome is associated with elevated plasma soluble CD40 ligand, a marker of coronary artery disease. Fertil Steril 91:2545–2550CrossRefPubMed
12.
go back to reference Schonbeck U, Varo N, Libby P, Buring J, Ridker PM (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104:2266–2268CrossRefPubMed Schonbeck U, Varo N, Libby P, Buring J, Ridker PM (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104:2266–2268CrossRefPubMed
13.
go back to reference Geraldes P, Gagnon S, Hadjadj S, Merhi Y, Sirois MG, Cloutier I, Tanguay JF (2006) Estradiol blocks the induction of CD40 and CD40L expression on endothelial cells and prevents neutrophil adhesion: an ER alpha-mediated pathway. Cardiovasc Res 71:566–573CrossRefPubMed Geraldes P, Gagnon S, Hadjadj S, Merhi Y, Sirois MG, Cloutier I, Tanguay JF (2006) Estradiol blocks the induction of CD40 and CD40L expression on endothelial cells and prevents neutrophil adhesion: an ER alpha-mediated pathway. Cardiovasc Res 71:566–573CrossRefPubMed
14.
go back to reference Lahita RG (2000) Sex hormones and systemic lupus erythematosus. Rheum Dis Clin North Am 26:951–968CrossRefPubMed Lahita RG (2000) Sex hormones and systemic lupus erythematosus. Rheum Dis Clin North Am 26:951–968CrossRefPubMed
15.
go back to reference Rider V, Jones S, Evans M, Bassiri H, Afsar Z, Abdou NI (2001) Estrogen increases CD40 ligand expression in T cells from women with systemic lupus erythematosus. J Rheumatol 28:2644–2649PubMed Rider V, Jones S, Evans M, Bassiri H, Afsar Z, Abdou NI (2001) Estrogen increases CD40 ligand expression in T cells from women with systemic lupus erythematosus. J Rheumatol 28:2644–2649PubMed
16.
go back to reference Abdou NI, Rider V, Greenwell C, Li X, Kimler BF (2008) Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial. J Rheumatol 35:797PubMed Abdou NI, Rider V, Greenwell C, Li X, Kimler BF (2008) Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial. J Rheumatol 35:797PubMed
17.
18.
go back to reference Tsytsykova AV, Tsitsikov EN, Geha RS (1996) The CD40L promoter contains nuclear factor of activated T cells-binding motifs which require AP-1 binding for activation of transcription. J Biol Chem 271:3763–3770CrossRefPubMed Tsytsykova AV, Tsitsikov EN, Geha RS (1996) The CD40L promoter contains nuclear factor of activated T cells-binding motifs which require AP-1 binding for activation of transcription. J Biol Chem 271:3763–3770CrossRefPubMed
19.
go back to reference Wagner AH, Gebauer M, Pollok-Kopp B, Hecker M (2002) Cytokine-inducible CD40 expression in human endothelial cells is mediated by interferon regulatory factor-1. Blood 99:520–525CrossRefPubMed Wagner AH, Gebauer M, Pollok-Kopp B, Hecker M (2002) Cytokine-inducible CD40 expression in human endothelial cells is mediated by interferon regulatory factor-1. Blood 99:520–525CrossRefPubMed
Metadata
Title
Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients
Authors
Levent Kebapcilar
Oktay Bilgir
Cuneyt Eftal Taner
Ayse Gul Kebapcilar
Didem L. Kozaci
Ahmet Alacacioglu
Yasar Yildiz
Arif Yuksel
Ismail Sari
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
Archives of Gynecology and Obstetrics / Issue 3/2010
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-009-1189-7

Other articles of this Issue 3/2010

Archives of Gynecology and Obstetrics 3/2010 Go to the issue